285 related articles for article (PubMed ID: 37142447)
1. Process engineering of natural killer cell-based immunotherapy.
Motallebnejad P; Kantardjieff A; Cichocki F; Azarin SM; Hu WS
Trends Biotechnol; 2023 Oct; 41(10):1314-1326. PubMed ID: 37142447
[TBL] [Abstract][Full Text] [Related]
2. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
3. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
4. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
5. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
6. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
7. A clinically relevant large-scale biomanufacturing workflow to produce natural killer cells and natural killer cell-derived extracellular vesicles for cancer immunotherapy.
St-Denis-Bissonnette F; Cummings SE; Qiu S; Stalker A; Muradia G; Mehic J; Mediratta K; Kaczmarek S; Burger D; Lee SH; Wang L; Lavoie JR
J Extracell Vesicles; 2023 Dec; 12(12):e12387. PubMed ID: 38054534
[TBL] [Abstract][Full Text] [Related]
8. Non-viral engineering of NK cells.
Hinnekens C; De Smedt SC; Fraire JC; Braeckmans K
Biotechnol Adv; 2023 Nov; 68():108212. PubMed ID: 37454745
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic natural killer cell therapy.
Berrien-Elliott MM; Jacobs MT; Fehniger TA
Blood; 2023 Feb; 141(8):856-868. PubMed ID: 36416736
[TBL] [Abstract][Full Text] [Related]
11. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
13. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell lines in tumor immunotherapy.
Cheng M; Zhang J; Jiang W; Chen Y; Tian Z
Front Med; 2012 Mar; 6(1):56-66. PubMed ID: 22460449
[TBL] [Abstract][Full Text] [Related]
15. Breaking boundaries: Current progress of anticancer NK cell-based drug development.
Wang S; Chen K; Jiang Y; Zhao G; Wang C; Fang H; Tang Q; Sun C; Zhang L; Wu H; Zhang LF; Li N
Drug Discov Today; 2023 Feb; 28(2):103436. PubMed ID: 36370993
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
17. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
18. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
[TBL] [Abstract][Full Text] [Related]
19. Nonviral genome engineering of natural killer cells.
Robbins GM; Wang M; Pomeroy EJ; Moriarity BS
Stem Cell Res Ther; 2021 Jun; 12(1):350. PubMed ID: 34134774
[TBL] [Abstract][Full Text] [Related]
20. Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions
Oyer JL; Croom-Perez TJ; Dieffenthaller TA; Robles-Carillo LD; Gitto SB; Altomare DA; Copik AJ
Front Immunol; 2022; 13():861681. PubMed ID: 35464440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
